Guided Therapeutics (GTHP) Gross Margin (2010 - 2025)

Guided Therapeutics has disclosed Gross Margin across 16 years of filings, most recently posting 77.63% for Q4 2025.

• Gross Margin for Q4 2025 came in at 77.63%, up 27763.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 74.58% (up 4600.0% YoY), and the FY2025 annual result was 74.45%, up 4587.0% from the prior year.
• Gross Margin came in at 77.63% for Q4 2025 at Guided Therapeutics, up from 58.33% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 100.0% in Q2 2021 to a low of 200.0% in Q4 2024.
• The 5-year median for Gross Margin is 67.09% (2024), against an average of 36.54%.
• Across the five-year window, Gross Margin plunged 27167 bps in 2021 and soared 27763 bps in 2025, its largest moves.
• Guided Therapeutics' Gross Margin stood at 68.33% in 2021, then surged by 46 bps to 100.0% in 2022, then slumped by 50 bps to 50.0% in 2023, then tumbled by 500 bps to 200.0% in 2024, then soared by 139 bps to 77.63% in 2025.
• The last three Gross Margin figures came in at 77.63% (Q4 2025), 58.33% (Q3 2025), and 67.52% (Q2 2025), per Business Quant data.